HemCon Medical Technologies, Inc. And ProMetic BioSciences, Inc. Announce Collaborative Development Agreement

PORTLAND, Ore. & CAMBRIDGE, England--(BUSINESS WIRE)--HemCon Medical Technologies Inc. (“HemCon”), a leading global developer of advanced medical products, today announced a new collaborative development agreement with ProMetic Life Sciences Inc.’s (“ProMetic”) UK-based division, ProMetic BioSciences Ltd that specializes in separation products and technologies for use in the manufacturing of biopharmaceutical products. Together, HemCon and ProMetic will develop and validate a sterile, single-use antibody capture device for the removal of isoagglutinin antibodies.